跳至主要内容
临床试验/JPRN-UMIN000025290
JPRN-UMIN000025290已完成未知

Observational biomarker study related to the resistance mechanism of 3rd generation EGFR-TKI (osimertinib)(LOGIK1607) - Observational biomarker study related to the resistance mechanism of osimertinib (LOGIK1607)

Clinical Research Support Center Kyushu0 个研究点目标入组 40 人开始时间: 2016年12月15日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients who receive osimertinib concurrently with other cytotoxic agents, molecular targeting agents or immune-checkpoint inhibitors are excluded. Patients whose tumor specimens cannot meet the eligibility criteria or the "paired" specimens (pre and post osimertinib treatment) cannot be submitted are also excluded.

研究者

发起方
Clinical Research Support Center Kyushu

相似试验